Skip to Content

ASCO 2019: Maintenance Therapy with PARP Inhibitor Olaparib Delays Progression of BRCA-related Pancreatic Cancer

This is the first phase III trial to evaluate efficacy of maintenance treatment with a PARP inhibitor, olaparib, for Pancreatic cancer patients with a germline BRCA1and/or BRCA2mutation. In this MEDtalk, Hedy L. Kindler, concludes, that Maintenance olaparib provided a statistically significant and clinically meaningful improvement in PFS for this group of patients.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top